In lymphoma, DNMT3B expression was also increased in BL,52 DLBCL53, and plasmablastic lymphoma (PBL),170 and it was identified as an adverse prognostic factor.53DNMT3B overexpression was associated with advanced clinical stages and resistance to treatment in DLBCL.53 However, studies also found that the expression of DNMT3B was lower in PGI-DLBCL patients.54 In MM, the expression of DNMT3B was increased in in U266 and RPMI8226 myeloma cells.58,171. The gene discussed is DNMT3B; the disease is plasma cell myeloma.